Ignet

Gene Information

Gene symbol: HLA-DQB1

Gene name: major histocompatibility complex, class II, DQ beta 1

HGNC ID: 4944

Synonyms: IDDM1, CELIAC1

Related Genes

#	Gene Symbol	Number of hits
1	ARID4A	1 hits
2	CD4	1 hits
3	CD8A	1 hits
4	HCRTR2	1 hits
5	HLA-A	1 hits
6	HLA-C	1 hits
7	HLA-DMA	1 hits
8	HLA-DOA	1 hits
9	HLA-DOB	1 hits
10	HLA-DPB1	1 hits
11	HLA-DQA1	1 hits
12	HLA-DQB2	1 hits
13	HLA-DRA	1 hits
14	HLA-DRB1	1 hits
15	HLA-DRB3	1 hits
16	HLA-DRB4	1 hits
17	HLA-DRB5	1 hits
18	HLA-G	1 hits
19	HLA-H	1 hits
20	IFNG	1 hits
21	MLANA	1 hits
22	PSMB8	1 hits
23	PSMB9	1 hits
24	TAP1	1 hits
25	TAP2	1 hits
26	TNFRSF25	1 hits

Related Sentences

#	PMID	Sentence
1	8058747	A synthetic peptide from the third hypervariable region of major histocompatibility complex class II beta chain as a vaccine for treatment of experimental autoimmune encephalomyelitis.
2	9243749	The HLA type of these individuals and of 248 controls were determined by serology for HLA class I and by molecular typing for the HLA class II loci DRB1 and DQB1.
3	9243749	Subsequent analysis of the results revealed that HLA-DRB10701 and HLA-DQB102 were significantly associated with antibody non-response to the "S"-containing vaccine compared with the HLA control population.
4	9243749	The hepatitis B surface antigen antibody results from this group of patients show that 30 of the 86 individuals remained antibody non-responders and that 24 individuals (80%) expressed the HLA-DQB102 and that 21 individuals (70%) expressed HLA-DRB10701.
5	9243749	The HLA type of these individuals and of 248 controls were determined by serology for HLA class I and by molecular typing for the HLA class II loci DRB1 and DQB1.
6	9243749	Subsequent analysis of the results revealed that HLA-DRB10701 and HLA-DQB102 were significantly associated with antibody non-response to the "S"-containing vaccine compared with the HLA control population.
7	9243749	The hepatitis B surface antigen antibody results from this group of patients show that 30 of the 86 individuals remained antibody non-responders and that 24 individuals (80%) expressed the HLA-DQB102 and that 21 individuals (70%) expressed HLA-DRB10701.
8	9724784	We have taken advantage of class II-deficient (Ab0) mice, transgenic for either HLA-DRA/B10301 (DR3) or HLA-DQB10302/DQA*0301 (DQ8) alleles.
9	10319881	HLA-DRB1, HLA-DQB1, and TCRBV gene polymorphisms were studied in Thai individuals with SAE (n = 18), with vaccination without neurological complications (n = 43), and without vaccination (n = 140).
10	10663576	The major and a minor class II beta-chain (B-LB ) gene flank the Tapasin gene in the B-F /B-L region of the chicken major histocompatibility complex.
11	10663576	We have identified the major histocompatibility complex class II beta-chain (B-LB) genes present in the B-F/B-L region of the B complex of nine well-characterized lines of chickens and have cleared up much of the confusion concerning numbers and location of B-LB genes in this region.
12	10663576	The dominantly expressed 'major' B-LB gene in all haplotypes lies between Tapasin and RING-3, and belongs to the B-LBII family of class II beta-chain genes.
13	10663576	The poorly expressed 'minor' B-LB gene in all haplotypes lies between B-lec1 and Tapasin, and belongs either to the B-LBII family or to the previously unmapped B-LBVI family of class II beta-chain genes.
14	11112362	A subgroup of 96 babies also underwent HLA class III (C4A and C4B) typing.
15	11112362	Different HLA products seem to act as agonists (C4AQ0 and HLA-DQB1()02) or antagonists (C4AQ0, HLA-DQB1()02, and HLA-DRB1()11, DQB1()0301) in lowering humoral response to HBV vaccine.
16	11756990	When the nonresponders and responders with HLA class II were compared, the nonresponder group had more HLA-DRB107-positive donors (13/32 vs. 6/41 responders; P=.016, Fisher's exact test) and fewer HLA-DQB10603-9/14-positive donors (2/32 vs. 14/41 responders; P=.0045).
17	12543794	By comparison with local cadaver controls typed for HLA class I (n = 946) and II (n = 144) antigens, HPV-16-positive high grade vulval intraepithelial neoplasia patients (n = 42) showed significantly different frequencies of HLA-A2 [odds ratio (OR), 2.1; confidence interval (CI), 1.4-3.9], HLA-B7 (OR, 2.6; CI, 1.4-4.7), HLA-DRB101(01/02/04) (OR, 0.1; CI, 0.03-0.5), HLA-DRB111 (OR, 3.3; CI, 1.4-7.1), HLA-DRB113 (OR, 0), HLA-DQB105 (OR, 0.2; CI, 0.05-0.6), and HLA-DQB1*03032 (OR, 4.6; CI, 1.5-14.0).
18	17082590	Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
19	17082590	In this study, we describe two novel Melan-A/MART-1-derived sequences recognized by CD4 T cells from melanoma patients.
20	17082590	These epitopes can be mimicked by peptides Melan-A27-40 presented by HLA-DRB10101 and HLA-DRB10102 and Melan-A25-36 presented by HLA-DQB10602 and HLA-DRB10301.
21	17082590	CD4 T cell clones specific for these epitopes recognize Melan-A/MART-1+ tumor cells and Melan-A/MART-1-transduced EBV-B cells and recognition is reduced by inhibitors of the MHC class II presentation pathway.
22	17082590	Moreover, Melan-A-specific Abs could be detected in the serum of patients with measurable CD4 T cell responses specific for Melan-A/MART-1.
23	17082590	Interestingly, even the short Melan-A/MART-1(26-35(A27L)) peptide was recognized by CD4 T cells from HLA-DQ6+ and HLA-DR3+ melanoma patients.
24	17082590	Using Melan-A/MART-1(25-36)/DQ6 tetramers, we could detect Ag-specific CD4 T cells directly ex vivo in circulating lymphocytes of a melanoma patient.
25	17082590	Together, these results provide the basis for monitoring of naturally occurring and vaccine-induced Melan-A/MART-1-specific CD4 T cell responses, allowing precise and ex vivo characterization of responding T cells.
26	17106278	We found 10 class I alleles present in more than 10% of the population: HLA-A02, HLA-A11, HLA-A24, HLA-B13, HLA-B15, HLA-B40, HLA-Cw03, HLA-Cw07, HLA-Cw01, and HLA-Cw06.
27	17106278	Several class II alleles were found at high frequency (>or=10%): HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRB10701, HLA-DRB11501, HLA-DRB10401, HLA-DRB10901, HLA-DRB11201, HLA-DQB10601, HLA-DQB10301, HLA-DQB10201, HLA-DQB10501, and HLA-DQB0303.
28	17106278	The HLA-B14 allele was only found in the HIV-1-seropositive group, and many 2-locus haplotypes were significantly overrepresented in this group: HLA-B14/Cw08, HLA-B51/Cw14, HLA-A02/B13, HLA-A31/Cw14, HLA-A02/Cw06, and the class II haplotype HLA-DRB11301/DQB1*0601.
29	17106278	Alleles significantly increased in the HIV-1-seronegative controls were HLA-B44, HLA-Cw04, and HLA-DRB1*1402.
30	17106278	Overrepresented 2-locus haplotypes in the control group were HLA-B44/Cw04, HLA-A31/Cw03, HLA-A03/Cw07, HLA-A11/B13, HLA-A11/B38, HLA-A24/B52, and HLA-A11/Cw01.
31	17215337	We studied the association between HLA alleles and rubella-specific gamma interferon (IFN-gamma) (Th1) and interleukin-10 (IL-10) (Th2) cytokine responses among 106 healthy children (ages, 14 to 17 years) previously immunized with two doses of rubella vaccine.
32	17215337	Several class I HLA-A (0201, 2402, *6801) alleles were significantly associated with rubella vaccine-induced IFN-gamma secretion.
33	17215337	Several class II HLA-DRB1 (0101) and HLA-DQB1 (0501) alleles were also suggestive of an association with IFN-gamma secretion.
34	17215337	Alleles with potential associations with rubella-specific IL-10 production included HLA-A (0201, 6801), HLA-B (4901), and HLA-DRB1 (1302).
35	17215337	The class I A0201 and A6801 alleles were associated with both IFN-gamma and IL-10 secretion.
36	17318652	A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
37	17318652	Here we describe a new Melan-A/MART-1 epitope recognized in the context of HLA-DQa10101 and HLA-DQb10501, -DQb10502 or -DQb10504 molecules by a CD4+ T cell clone.
38	17318652	Importantly, this clone specifically recognizes and kills tumor cell lines expressing Melan-A and either HLA-DQb10501, -DQb10504 or -DQb1*0502 molecules.
39	17318652	Moreover, we could detect CD4+ T cells secreting IFN-gamma in response to Melan-A51-63 and Melan-A51-73 peptides among tumor infiltrating and blood lymphocytes from HLA-DQ5+ patients.
40	17318652	A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
41	17318652	Here we describe a new Melan-A/MART-1 epitope recognized in the context of HLA-DQa10101 and HLA-DQb10501, -DQb10502 or -DQb10504 molecules by a CD4+ T cell clone.
42	17318652	Importantly, this clone specifically recognizes and kills tumor cell lines expressing Melan-A and either HLA-DQb10501, -DQb10504 or -DQb1*0502 molecules.
43	17318652	Moreover, we could detect CD4+ T cells secreting IFN-gamma in response to Melan-A51-63 and Melan-A51-73 peptides among tumor infiltrating and blood lymphocytes from HLA-DQ5+ patients.
44	17381721	HLA-DQB1 and HLA-DRB1 alleles were also determined.
45	17438108	HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions.
46	21872631	We found significant associations with class I HLA-B (p=0.05) as well as class II HLA-DPB1 (p=0.01) and -DPA1 (p=0.03) genes for measles vaccine-induced antibody levels after the second dose.
47	21872631	Similarly, we found significant associations with class II HLA-DQB1 (p=0.05) and -DRB1 (p=0.01) genes for measles-specific lymphoproliferation after the second dose.
48	22649493	Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3α and MSP-9 in individuals from Brazilian endemic area.
49	23649091	Similarly, we found that class I (HLA-A) and class II (HLA-DQA1 and HLA-DQB1) homozygosity was significantly associated with an overall decrease in LP compared with heterozygosity at those three loci.
50	23649091	Specifically, individuals who were homozygous at these loci had significantly lower PA-specific LP than subjects heterozygous for HLA-A (median SI, 1.48 versus 2.13, P = 0.005), HLA-DQA1 (median SI, 1.75 versus 2.11, P = 0.007), and HLA-DQB1 (median SI, 1.48 versus 2.13, P = 0.002) loci, respectively.
51	23649091	Similarly, we found that class I (HLA-A) and class II (HLA-DQA1 and HLA-DQB1) homozygosity was significantly associated with an overall decrease in LP compared with heterozygosity at those three loci.
52	23649091	Specifically, individuals who were homozygous at these loci had significantly lower PA-specific LP than subjects heterozygous for HLA-A (median SI, 1.48 versus 2.13, P = 0.005), HLA-DQA1 (median SI, 1.75 versus 2.11, P = 0.007), and HLA-DQB1 (median SI, 1.48 versus 2.13, P = 0.002) loci, respectively.
53	24075919	These SNPs were found to regulate the expression of a group of genes involved in antigen processing and presentation including HLA-A, HLA-C, HLA-G, HLA-H, HLA-DRA, HLA-DRB1, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DOB, and TAP-2.
54	24728075	Hypomethylation of CpGs located in 6p21.3 in the R class associated with cis upregulation of genes enriched in immune response processes (TAP1, PSMB8, PSMB9, HLA-DQB1, HLA-DQB2, HLA-DMA, and HLA-DOA), increased CD8 T-cell tumor infiltration (P=7.6×10(-5)), and trans-regulation of genes in immune-related pathways (P=1.6×10(-32)).
55	25148251	HLA-DRB1 and HLA-DQB1 allelic groups were typed by PCR-SSO to evaluate the association between major HLA class II alleles and antibody responses.
56	25148251	Although 52.9% of the population did not present detectable titers of antibodies to PvRMC-RBP1, genetic restriction to this chimeric protein does not seem to occur, since no association was observed between the HLA-DRB1* or HLA-DQB1* alleles and the antibody responses.
57	25148251	HLA-DRB1 and HLA-DQB1 allelic groups were typed by PCR-SSO to evaluate the association between major HLA class II alleles and antibody responses.
58	25148251	Although 52.9% of the population did not present detectable titers of antibodies to PvRMC-RBP1, genetic restriction to this chimeric protein does not seem to occur, since no association was observed between the HLA-DRB1* or HLA-DQB1* alleles and the antibody responses.
59	25626602	We genotyped the classical HLA-DRB1, DQB1, and DPB1 genes in 450 individuals from the placebo arm of the RV144 study to determine the background allele and haplotype frequencies of these genes in this cohort.
60	25626602	The observed diversity for the HLA loci was 33 HLA-DRB1, 15 HLA-DQB1, and 26 HLA-DPB1 alleles.
61	26136476	A significant proportion of sera from HLA-DQB1*0602 haplotype-positive narcoleptic Finnish patients with a history of Pandemrix vaccination (vaccine-associated narcolepsy) contained antibodies to hypocretin receptor 2 compared to sera from nonnarcoleptic individuals with either 2009 A(H1N1) pandemic influenza infection or history of Focetria vaccination.